Outcomes | Conditions | Data availability |
---|---|---|
Adverse 1 | Treatment with bDMARD within 2 years | 118/118 |
Adverse 2 | HAQ > 1 or DAS28 > 5.1 while on csDMARDs or treatment with bDMARD at 2 years | 94/118 |
Favorable | DAS28 < 3.2 and HAQ ≤ 0.25 and no treatment with bDMARD at 2 years | 93/118 |